SIGA

SIGA Technologies, Inc. - 10-Q Summary (Quarter Ended September 30, 2005)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2005, for SIGA Technologies, Inc., a Delaware corporation engaged in the research and development of novel products for infectious diseases and biological warfare defense. The company has no commercial products and relies on government grants (primarily NIH SBIR) and contracts (e.g., U.S. Army) for revenue. Management states that the financial statements assume the company will continue as a going concern, though this is dependent on securing additional financing.

Key Financial Metrics

Debt: The company holds a note payable of $241,106 total ($107,520 current; $133,586 non-current) to General Electric Capital Corporation at 10.31% interest.

Material Changes vs. Prior Period

• Revenue Surge: Revenues increased significantly from $532,724 in Q3 2004 to $2,910,065 in Q3 2005. This is primarily due to the recognition of revenue from NIH SBIR grants awarded in late 2004 and a new contract with the U.S. Army Medical Research and Material Command (USAMRMC).
• Profitability Shift: The company reported a net profit of $723,761 for Q3 2005, compared to a net loss of $1,837,353 in Q3 2004. This turnaround was driven by the revenue increase and a 55% reduction in Selling, General, and Administrative (SG&A) expenses.
• Expense Reduction: SG&A expenses dropped to $415,275 in Q3 2005 from $919,165 in Q3 2004. This decline included a $200,000 credit from renegotiated legal invoices and reduced legal fees compared to the prior year's acquisition-related costs.
• R&D Increase: Research and development expenses rose 113% to $1,764,980 in Q3 2005 from $826,827 in Q3 2004, driven by preclinical development work and the hiring of eight additional scientists.
• Cash Position: Cash and cash equivalents decreased from $2,020,938 at year-end 2004 to $193,856 at September 30, 2005, reflecting a net cash outflow of $1.8 million for the nine-month period.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash and anticipated government funding will support operations through the third quarter of 2006. However, the company expects to incur additional losses and requires further financing to complete product development.
• Recent Financing: On November 2, 2005 (post-period), the company entered an agreement to sell 2,000,000 shares of common stock and warrants, receiving gross proceeds of $2,000,000 on November 3, 2005.
• Key Risks:
  • Going Concern: Continuation of operations depends on the success of R&D programs and the ability to obtain adequate financing.
  • Development Risk: All product programs are in early stages; there is a high risk of non-completion, and commercial products are not expected for one to three years, if at all.
  • Funding Dependency: Significant reliance on government grants and contracts; failure to secure these could suspend development timelines.
• Unusual Items: The Q3 2005 profit includes a $200,000 legal expense credit. The prior year (2004) included a $610,000 impairment charge on intangible assets and $568,000 in purchased in-process R&D expenses, which are not present in the 2005 period.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $193,856 cash balance against the burn rate and the timing of expected government grant payments.
• Revenue Recognition: Confirm the sustainability of revenue streams, noting that 92% of Q3 2005 revenue came from NIH SBIR grants.
• Post-Period Financing: Review the terms and closing status of the $2,000,000 equity financing announced in November 2005.
• Debt Obligations: Assess the impact of the $241,106 note payable (10.31% interest) on future cash flows.
• R&D Milestones: Evaluate the progress of the Smallpox and Arenavirus programs, as commercialization is projected to be 1-3 years away.